Abstracts tagged "autoantibodies"

Abstract Number: 2366 • 2015 ACR/ARHP Annual Meeting
The Anti-MDA5 Autoantibody Phenotype: Defining Clinical, Biochemical and Radiological Features Suggestive of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease
Sabrina Hoa¹, Yves Troyanov¹, Marvin J. Fritzler², Ira N. Targoff³, Anne-Marie Mansour¹, Eric Rich¹, Hind Boudabbouz¹, Josiane Bourré-Tessier¹, Sandra Chartrand¹, Marianne Landry¹, Martin Albert¹ and Jean-Luc Senécal¹, ¹Université de Montréal, Montreal, QC, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Anti-MDA5 autoantibody associated syndrome is a novel entity within the spectrum of autoimmune myositis. It has been described as a clinical mimic of the…
Abstract Number: 740 • 2015 ACR/ARHP Annual Meeting
The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus
May Choi¹, John G. Hanly², Murray Urowitz^3,4, Juanita Romero-Diaz⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Sasha Bernatsky⁸, Daniel J Wallace⁹, Joan T. Merrill¹⁰, David A. Isenberg¹¹, Anisur Rahman¹², Ellen M. Ginzler¹³, Paul R. Fortin¹⁴, Dafna Gladman¹⁵, Jorge Sanchez-Guerrero¹⁶, Michelle Petri¹⁷, Ian N. Bruce¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Cynthia Aranow²¹, Graciela S. Alarcon²², Kristján Steinsson²³, Ola Nived²⁴, Gunnar K. Sturfelt²⁵, Susan Manzi²⁶, Munther Khamashta²⁷, Ronald F. van Vollenhoven²⁸, Asad Zoma²⁹, Guillermo Ruiz-Irastorza³⁰, S. Sam Lim³¹, Thomas Stoll³², Murat Inanc³³, Kenneth C. Kalunian³⁴, Diane L. Kamen³⁵, Peter Maddison³⁶, Christine A. Peschken³⁷, Søren Jacobsen³⁸, Anca Askanase³⁹, Jill P. Buyon⁴⁰, W. Winn Chatham⁴¹, Manuel Ramos-Casals⁴², Yvan St. Pierre⁴³, Ann E. Clarke⁴⁴ and Marvin J. Fritzler¹, ¹Medicine, University of Calgary, Calgary, AB, Canada, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Rheumatology, TWH, Toronto, ON, Canada, ⁴Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁶Rheumatology (East Wing), Medical School, Birmingham, United Kingdom, ⁷Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁸Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁹Cedars-Sinai Medical Center, West Hollywood, CA, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹²Centre for Rheumatology Research, U College of London, London, United Kingdom, ¹³Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹⁴Rheumatology, University of Laval, Quebec, QC, Canada, ¹⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁶Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ¹⁷Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ¹⁸Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ¹⁹UNC Kidney Centre, Chapel Hill, NC, ²⁰Northwestern University Feinberg School of Medicine, Chicago, IL, ²¹Feinstein Institute for Medical Research, Mahasset, NY, ²²Medicine, University of Alabama at Birmingham, Birmingham, AL, ²³Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁴Rheumatology, Inst of Clinical sciences, Lund, Sweden, ²⁵Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ²⁶Rheumatology, Allegheny Health Network, Pittsburgh, PA, ²⁷Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ²⁸Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²⁹Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³⁰Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, ³¹Emory University School of Medicine, Atlanta, GA, ³²Abteilung Rheumatologie/Rehab, Kantonsspital Schaffhausen, Schaffhausen, Switzerland, ³³Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁴Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³⁵Medicine, Medical University of South Carolina, Charleston, SC, ³⁶School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, ³⁷Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, ³⁸Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁹Columbia University College of Physicians & Surgeons, New York, NY, ⁴⁰Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴¹Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴²Department of Autoimmune Diseases, CELLEX-IDIBAPS, Hospital Clínic, Barcelona, Barcelona, Spain, ⁴³Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴⁴Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada
Background/Purpose: Autoantibodies to the nuclear autoantigen dense fine speckles 70 (DFS70) are associated with a new paradigm whereby when they are found in isolation (monospecific…
Abstract Number: 1463 • 2015 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibody Subclass Phenotypes in Polyarticular Juvenile Idiopathic Arthritis
Hannah Peckham¹, Lauren Bourke^2,3, Anna Radziszewska⁴, Maria Leandro⁵, Debajit Sen², Geraldine Cambridge⁶ and Yiannis Ioannou^7,8, ¹Adolescent Centre for Rheumatology Research, University College London, London, United Kingdom, ²Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴The Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁵Centre for Rheumatology, University College London, London, United Kingdom, ⁶Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁷Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁸Centre for Rheumatology Research, University College Hospital London, London, United Kingdom
Background/Purpose: Raised levels of Rheumatoid Factor (RhF) and antibodies to citrullinated proteins (ACPA), detected in the clinic using combinations of cyclic citrullinated peptides (CCP), are…
Abstract Number: 2368 • 2015 ACR/ARHP Annual Meeting
Myositis Specific-Autoantibodies: Predictors of Short-Term Good Outcome in Rituximab Treated-Refractory Idiopathic Inflammatory Myopathies
Fernando Henrique Carlos de Souza¹, Renata Miossi², Julio C. B. Moraes¹, Karina Bonfiglioli¹, Eloisa Bonfá¹ and Samuel Katsuyuki Shinjo¹, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: The treatment of idiopathic inflammatory myopathies (IIM) is challenging, complicated by its rarity and heterogeneity. Currently few studies have suggested the efficacy of RTX…
Abstract Number: 2698 • 2014 ACR/ARHP Annual Meeting
Survival in Systemic Sclerosis-Pulmonary Arterial Hypertension By Serum Autoantibody Status
Monique Hinchcliff^1,2, Saira Khanna³, Jungwha Lee^4,5, Orit Almagor⁶, Rowland W. Chang^2,7, Virginia D. Steen⁸ and Lorinda Chung⁹, ¹Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Preventive Medicine, Northwestern University Medical School, Chicago, IL, ⁶Northwestern University, Chicago, IL, ⁷Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁹Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Previous studies have shown that anticentromere (AC) and isolated nucleolar (NUC) antibodies are the most common autoantibodies in patients with systemic sclerosis (SSc) and…
Abstract Number: 1262 • 2014 ACR/ARHP Annual Meeting
Mechanisms of Muscular Necrosis in Auto-Immune Myopathies Associated with Anti-Signal Recognition Particle and Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Antibodies: Pathogenic Role of Auto-Antibodies
Yves Allenbach^1,2,3, Aude Rigolet³, Bruno Eymard⁴, Tanya Stojkovic⁴, Anthony. Behin⁴, Pascal Laforet⁴, Peter Hufnagl⁵, Norman Zerbe⁶, Thierry Maisonobe⁷, Kuberaka Mariampillai⁸, Serge Herson⁸, Olivier Benveniste^2,3 and Werner Stenzel⁹, ¹Neuropathology, Charite Hospital, Berlin, Germany, ²UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, ³Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Department of Neurology, Myology Institute, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, ⁵Pathology departmen, Charite Hospital, Berlin, Germany, ⁶Department of Pathology, Charite Hospital, Berlin, Germany, ⁷Neuropathology, Pitie-Salpetriere Hospital, Paris, France, ⁸Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, ⁹Department of Neuropathology, Charite Hospital, Berlin, Germany
Background/Purpose: Necrotizing auto-immune myopathies (NAM) are a group of acquired idiopathic inflammatory myopathies characterized by severe muscle weakness and no or mild extra-muscular involvement. Definition of…
Abstract Number: 638 • 2014 ACR/ARHP Annual Meeting
Commensal Microbiota Influence Systemic Autoimmune Responses
Jens Van Praet¹, Erin Donovan², Michael Drennan¹, Fons Van de Loo³, Sylvie Rabot⁴, Jeroen Raes⁵, Tom Van De Wiele⁶, Carl Ware⁷ and Dirk Elewaut⁸, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²department of Rheumatology, Ghent University Hospital, ghent, Belgium, ³Rheumatology, Raboud University Medical Center, Utrecht, Netherlands, ⁴AgroParisTech, Micalis,, Jouy-en-Josas, France, ⁵Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium, ⁶Laboratory of Microbial Ecology and Technology, Ghent University Hospital, Ghent, Belgium, ⁷Infectious and Inflammatory Disease Center,, Sanford-Burnham Medical Research Institute, La Jolla, CA, ⁸Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium
Background/Purpose Antinuclear antibodies are a hallmark feature of generalized autoimmune diseases, including systemic lupus erythematosus and systemic sclerosis. However, the processes underlying the loss of…
Abstract Number: 2530 • 2014 ACR/ARHP Annual Meeting
PRE.MARK-TNF Test Based on Iga-Specific Autoantigens Predicts Therapy Response in Rheumatoid Arthritis Patients Treated with TNFα Inhibitors
Karl Skriner¹, Jörg Hollidt², Gerd Burmester³ and Zoltan Konthur⁴, ¹Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Drug Response DX GmbH, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Drug Response DX GmbH, Hennigsdorf, Germany
Background/Purpose One third of rheumatoid arthritis patients treated with biologicals targeting TNFα are therapy non-responders. We have earlier investigated the difference in seroreactivity of patients…
Abstract Number: 1272 • 2014 ACR/ARHP Annual Meeting
Myositis-Specific and Myositis Associated Autoantibodies in Indian Patients with Inflammatory Myositis
Puja Srivastava, Ramnath Misra, Able Lawrence, Amita Aggarwal and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose Recently, idiopathic inflammatory myositis (IIM) has been categorised into distinct subsets based on myositis specific autoantibodies (MSA) and myositis associated autoantibodies (MAA). However, there is…
Abstract Number: 442 • 2014 ACR/ARHP Annual Meeting
Anti-Carbamylated Protein Antibody Levels Are Elevated in Seropositive Rheumatoid Arthritis and Correlate with Anti-Sa/Citrullinated Vimentin Antibody Levels
Gregory J. Challener¹, Jonathan D. Jones², B. JoNell Hamilton¹, Gilles Boire³, Artur José de Brum-Fernandes⁴, Pierre Cossette⁵, Patrick Liang³, Ariel Masetto⁶, Nathalie Carrier⁷, Henri A. Ménard⁸ and William F.C. Rigby⁹, ¹Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, ²Rheumatology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Médecine, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Internal Medicine Departement, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸Rheumatology, Research Institute of the McGill University Health Center, Montreal, QC, Canada, ⁹Rheumatology; Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, NH
Background/Purpose: Recent studies indicate that the breach of immune tolerance that occurs in rheumatoid arthritis (RA) extends beyond the citrullination of arginines (as recognized by…
Abstract Number: 2457 • 2014 ACR/ARHP Annual Meeting
Anti-Major Histocompatibility Complex Class I-Related Chain a (MICA) Antibodies in Rheumatoid Arthritis Patients with Interstitial Lung Disease
Hiroshi Furukawa¹, Shomi Oka¹, Kota Shimada², Akiko Komiya¹, Naoshi Fukui¹, Naoyuki Tsuchiya³ and Shigeto Tohma¹, ¹Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ²Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ³Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Interstitial lung disease (ILD) is frequently associated with rheumatoid arthritis (RA), and is designated RA-associated ILD (RA-ILD) that influences the prognosis of the disease.…
Abstract Number: 1264 • 2014 ACR/ARHP Annual Meeting
Analysis of Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Severity of Physical Dysfunction after Treatment for Polymyositis and Dermatomyositis
Hidenaga Kawasumi¹, Takahisa Gono¹, Yasushi Kawaguchi¹, Yasuhiro Katsumata¹, Hisae Ichida¹, Akiko Tochimoto¹, Masanori Hanaoka¹, Yuko Okamoto¹, Sayuri Kataoka¹ and Hisashi Yamanaka², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Half of all polymyositis (PM)/dermatomyositis (DM) patients suffer from muscle weakness after initial treatment. Therefore, many patients with PM/DM have trouble with daily living…
Abstract Number: 455 • 2014 ACR/ARHP Annual Meeting
Clinical and Tissue Specificity of Antibodies Against Carbamylated Proteins in Patients with Rheumatoid Arthritis
Antonio Gonzalez¹, Ariana Montes¹, Eva Perez-Pampin¹, Maria Dolores Boveda² and Juan J. Gomez-Reino^1,3, ¹Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Laboratorio Metabolopatias, Insitituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ³Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
Background/Purpose Antibodies against carbamylated proteins (CarP) are a new type of autoantibodies specific of patients with rheumatoid arthritis (RA) relative to healthy controls, but their…
Abstract Number: 2392 • 2014 ACR/ARHP Annual Meeting
Anti-Carbamylated Antibodies (anti-CarPA) Are Associated with Long Term Disability and Increased Disease Activity in Patients with Early Inflammatory Arthritis: Results from the Norfolk Arthritis Register (NOAR)
Jenny H. Humphreys¹, Marije K Verheul², Anne Barton^3,4, Tarnya Marshall⁵, Bo Fu⁶, René E.M. Toes⁷, Deborah PM Symmons^1,4, Leendert A. Trouw⁷ and Suzanne MM Verstappen¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁶Centre for Biostatistics, Institute of Population Health, The University of Manchester, Manchester, United Kingdom, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-CarPA have been shown to predict development of rheumatoid arthritis (RA) in patients with arthralgia. However, little is known about their association with disease…
Abstract Number: 1260 • 2014 ACR/ARHP Annual Meeting
The Early Use of Cyclosporine Is Beneficial for Long-Term Prognosis in Patients of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease with Anti- Synthetase Antibodies
Yuji Hosono¹, Ran Nakashima², Yoshitaka Imura³, Naoichiro Yukawa², Hajime Yoshifuji², Takaki Nojima⁴, Koichiro Ohmura² and Tsuneyo Mimori², ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Interstitial lung disesases (ILD) is the most common cause of mortality in polymyosotis (PM) and dermatomyositis (DM). Cyclosporine had been reported to improve clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].